John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc.  John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives.) In 2001, Novazyme merged into Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey.  John is the author of a personal memoir:  Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard.  The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame.  John is a Henry Crown Fellow at the Aspen Institute.  He lives in Princeton, NJ with his wife, Aileen and their three children, John, Megan and Patrick. John serves on the executive committee of the National Board of Directors of the Make A Wish Foundation of America. 

From 1981-2006, Mr. Hayden had a highly-successful 25 year career in pharmaceuticals and related health care businesses with Bristol-Myers Squibb Company. Since March of 2006, Mr. Hayden has held key leadership roles at several venture-stage pharmaceutical and biotech companies.

At Bristol-Myers Squibb, Mr. Hayden served as executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing. Prior to that, Mr. Hayden held a number of senior management positions including vice president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice president for Worldwide Franchise Management and Business Development; president of Intercontinental and senior vice president, Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice president of Strategy; and executive vice president of the Health Care Group.

Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Amicus Therapeutics, Transave Inhalation Biotherapeutics, Vitae Pharmaceuticals and Gloucester Pharmaceuticals as well as serving as a Director of Cogentus Pharmaceuticals.

Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

Dr. Barer has been Chief Executive Officer of Celgene Corporation since May 1, 2006 and Chairman since January 1, 2007. He was appointed President of Celgene in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors. He previously served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from 1991 to 1994, and the Vice President, Technology, from 1987 to 1991. Dr. Barer is on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves on the Board of Trustees of the Biotechnology Council of New Jersey and is on the Board of the Brooklyn College Foundation. He has previously served as a Commissioner of the NJ Commission on Science and Technology. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University.

Dr. Barrett joined our board of directors in August 2009. Dr. Barrett currently serves as General Partner of New Enterprise Associates (NEA) where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA in 2001, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). He currently serves on the Board of Directors for several life sciences companies including Inhibitex, Inc. (NASDAQ: INHX) and Targacept, Inc. (NASDAQ: TRGT). Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Mr. Essner is Senior Advisor to the global healthcare group at The Carlyle Group, a global private equity firm. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth, now part of Pfizer, in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner is currently a Director at MassMutual Financial Group; NBTY, Inc., a leading nutritional supplement company; and Pharmaceutical Product Development, LLC (PPD), a major contract research organization. In addition, he is a trustee of the Children's Health Fund and Mote Marine Laboratories. Mr. Essner is also an Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in healthcare management. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago.

Dr. Love is currently at Onyx Pharmaceuticals, where he serves as Executive Vice President and Head of Research and Development and Technical Operations. He has overseen Onyx's first new drug application (NDA) submission, as well as the successful launch and execution of two global Phase 3 studies. From 2001 to 2009 Dr. Love served as Chief Executive Officer of Nuvelo, Inc., and served as Chairman and CEO from 2005 to 2009. Prior to Nuvelo, Dr. Love was Senior Vice President of Development at Theravance, Inc. He also held senior management positions in product development and medical affairs for six years at Genentech, where he was responsible for the overall drug development strategy and process that led to marketing approval of six new drugs. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Affymax, Inc., Bio-Rad Laboratories, Inc. and Santarus, Inc. He also served as a member of the Independent California Oversight Committee (ICOC) for Stem Cell Research. Dr. Love earned a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
 

Margaret G. McGlynn is President and CEO of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Margaret is an experienced biopharmaceutical executive with significant expertise in the vaccine and antiretroviral markets. She retired from Merck in 2009 after 26 years with the company. Her most recent role was President, Global Vaccines and Anti-Infectives, where she was responsible for a US$7 billion portfolio of products. In addition, she was very involved in global health, and she launched several initiatives to provide access for Merck vaccines and HIV therapies in the developing world. McGlynn also serves as a member of the Board of Directors for Air Products and Chemicals. She is a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences and served as a member of the Global Alliance for Vaccine Immunization (GAVI) Board and Executive Committee, a public-private partnership to bring life-saving vaccines against common infectious diseases to people across the developing world, where she played a major role in the formation of the Hilleman Center, a research center focused on developing new vaccines for the developing world, via a partnership between Merck and the Wellcome Trust. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.
 

Mr. Raab has been Chief Executive Officer and Chairman of Ardelyx since March 2009. He previously was a partner at NEA from 2002 and specialized in healthcare investments focusing on biotechnology and pharmaceutical sectors. Mr. Raab is also a member of the Healthcare Advisory Board of the Entrepreneurs Foundation and is a member of the Life Sciences Advisory Board for Silicon Valley Bank.

Prior to joining NEA, Mr. Raab spent 15 years in operating roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation. Prior to that, he was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of multiple new therapeutic products. He gained extensive international operational experience while building a commercial infrastructure in Latin America for the Therapeutics and Surgical Products groups for the company. Mr. Raab was also Product Manager for Ceredase and was instrumental in the worldwide launch of both Ceredase and Cerezyme, Genzyme's $1 billion therapies for Gaucher Disease. He also spent two years with Genzyme's Diagnostic products and services division. Previous to Genzyme, Mr. Raab held sales and marketing positions at Repligen and Bristol-Myers.

Mr. Raab received his B.A. from DePauw University.

Mr. Sblendorio joins the Amicus Board of Directors as the financial expert and will act as Chair of the audit committee. He currently serves as the Chief Financial Officer and Executive Vice President for The Medicines Company. Prior to joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for The Medicines Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio is also Chairman of NuLens Ltd., a medical device company that develops and manufactures intra-ocular lenses.

Dr. Topper has served as a member of the board of directors since 2004. He joined Frazier Healthcare in August 2003. He previously served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the VP of Biology at COR, and was responsible for managing all of its research activities. He has served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator.

Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. After completing a research fellowship in the Vascular Research Division in the department of Pathology at the Brigham and Women's hospital, he joined the faculty of Harvard Medical School from 1997-1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications, and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a Cardiology Consultant to the Palo Alto Veterans Administration Hospital.

Dr. Topper currently serves as an observer on the boards of CoTherix, Inc., and Portola Pharmaceuticals.